Physician profile
Anthony W Freda
NPI 1598745499
$1,064.02
in general payments reported to CMS, 2019-2025
20 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $103 · 2023: $13.52 · 2024: $29.98 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.98 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $170.75 | 2025 | Repatha, Otezla |
| Abbvie INC. | $134.61 | 2023-2025 | |
| Glaxosmithkline, LLC. | $91.67 | 2019-2020 | |
| Pfizer INC. | $68.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.96 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $34.09 | 2019-2020 | |
| Lilly USA, LLC | $33.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.17 | 2019 | |
| Merck Sharp & Dohme LLC | $24.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.66 | 2019 | |
| Astellas Pharma US INC | $20.40 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $13.00 | 2019 | |
| Amarin Pharma, INC. | $12.54 | 2019 | |
| Allergan, INC. | $11.82 | 2019 | |
| Shire North American Group INC | $11.22 | 2019 | |
| Supernus Pharmaceuticals, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Freda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.